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Abstract: Microarray studies have successfully shed light on various aspects of the molecular mechanisms behind the de-
velopment of hepatocellular carcinoma (HCC), such as the identification of novel molecular subgroups and the genetic 
profiles associated with metastasis and venous invasion. These experiments, mainly comprising genome wide profiling, 
potentially represent the basis of novel targeted therapeutic strategies in HCC. In response, we summarize the multiple re-
ported expression profiles in HCC associated with HCC development, novel subgroups, venous invasion and metastasis. 
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INTRODUCTION 
  Hepatocellular carcinoma is one of the most common 
cancers worldwide and the third most common cause of 
death due to cancer [1, 2]. Several etiological factors have 
been recognized, including viral hepatitis B (HBV) infection, 
hepatitis C (HCV) infection and alcohol abuse, although the 
molecular pathogenesis is not well-known [3, 4]. Few pa-
tients are eligible for surgery, the only curative treatment. 
The severity of this disease, the lack of good diagnostic 
markers and treatment strategies, as well as clinical hetero-
geneity have rendered the disease a major challenge [3]. 
Thus, a better understanding of the molecular pathogenesis 
of these tumors, through genome-wide gene expression stud-
ies, is crucial to overcoming these difficulties. 
HEPATOCELLULAR CARCINOMA 
  In most cases HCC arises in cirrhotic livers secondary to 
various environmental risk factors [5]. However, HCC may 
also develop in both normal liver, and abnormal non-
cirrhotic liver. HBV and HCV infections are the major risk 
factors, leading to cirrhosis and HCC. Other risk factors for 
liver cancer include alcohol abuse and aflatoxin B1 (AFB1) 
exposure [6]. 
  Each of above scenarios involves different genetic and 
epigenetic alterations, chromosomal aberrations, gene muta-
tions and differential activation/inhibition of molecular 
pathways [5]. Data from microarrays demonstrate different 
genetic profiles depending on the origin of the liver tumor, 
whether it arises in cirrhotic or non-cirrhotic liver, or within 
tumors in patients with HBV-infection, HCV-infection or 
alcohol abuse [5].  
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APPLICATIONS OF MICROARRAY TECHNOLOGY 
IN HCC RESEARCH 
  Microarray technology has been widely applied to iden-
tify the molecular and genomic mechanisms in liver tumori-
genesis. Over the past decade, a great variety of gene expres-
sion profile studies have been performed. 
  These studies have succeeded in further exploring the 
molecular basis of HCC development in a number of ways, 
namely by identifying specific gene expression patterns dis-
criminating HCC from non-tumor liver. This reveals consis-
tent gene expression patterns associated with etiological fac-
tors, histological phenotypes, and clinical phenotypes, as 
well as unveiling novel subtypes of HCC previously unrec-
ognized by conventional methods [3]. 
STUDIES DISCRIMINATING HCC FROM NON-
TUMOR LIVERS 
  The genomic signatures of HCC can be used to help 
characterize the molecular changes responsible for HCC 
development. With respect to clinical practice this will be 
particularly valuable in the development of novel tumor 
markers, with higher sensitivity than Alpha-Fetoprotein 
(AFP). Furthermore, large scale analysis of gene expression 
may be of significance in promoting the identification of 
novel therapeutic targets. For example, constantly upregu-
lated genes in HCC and their corresponding protein may be 
potential targets for a therapeutic intervention with a block-
ing antibody. Those strategies have been successfully intro-
duced in other cancers e.g. Her2neu blockade by Trastuzu-
mab in breast cancer. 
 Lau  et al. [7] were the first to use microarray technology 
to compare gene expression profiles of HCC and non-HCC 
liver tissues. Since then, multiple comparative studies have 
been published. Microarray analyses between HCC and non-
tumor tissues allowed the identification of a number of po-
tential genetic networks, deregulated in the context of liver 
carcinogenesis. Among these, Wnt-signaling pathway, p53-
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pathway were demonstrated to be differentially regulated by 
means of microarray experiments [8-12]. Looking at indi-
vidual genes, many of them have been identified as demon-
strating significantly altered expression between HCCs and 
non-tumor livers. However, confirming each and every one 
of these regulated genes from one microarray based analysis 
to the next remains difficult. Therefore, it seemed more use-
ful to focus on superimposed categories of genes. Some of 
the most differentially expressed categories of genes be-
tween HCC and non-tumor livers are genes related to cell 
cycle progression, RNA splicing, protein degradation, cell 
adhesion, metabolic enzymes, detoxification, immune re-
sponse, extracellular matrix and cytoskeleton, DNA damage 
repair system, and apoptosis, and also cytokines, growth 
factors, oncogenes, tumorsupressors, and GTP-binding pro-
teins [8, 9, 13-16]. 
  Many genes were significantly upregulated in HCC tis-
sue. Examples include those required for cell cycle progres-
sion whose expression levels correlated with cellular prolif-
eration rates, genes expressed in endothelial cells [13] regu-
lating the composition of the extracellular matrix and cy-
toskeleton [8, 14], and genes involved in DNA repair sys-
tems [8, 15]. Imprinted genes, and genes encoding secreted 
proteins [16], were also significantly upregulated. Further-
more, genes associated with immune response [8, 13, 14, 
16], coding for detoxification proteins [9, 10, 14], encoding 
metabolic enzymes [8, 9, 13, 14, 16], and many plasma pro-
tein coding genes [8, 9, 13, 14] were significantly down-
regulated in HCC tissues compared to adjacent non-
tumorous liver.  
  Besides the general mechanisms and genetic signatures 
associated with HCC development, it was noticed that the 
underlying chronic liver disease may significantly impact on 
the molecular mechanisms leading to HCC development. 
From a clinical point of view, this may account for the con-
siderable variance in risk of developing HCC among patients 
with different underlying chronic liver diseases [17, 18]. 
Currently most data analyzing the genetic signatures of HCC 
from patients with diverse underlying liver diseases focused 
on patients with HBV versus HCV infection [19-23]. The 
first genome-wide microarray study comparing HBV- with 
HCV-related HCC was performed by Okabe et al. [9]. Inter-
estingly, genes involved in drug metabolism and carcinogen 
detoxification were reported to be differentially regulated 
between HCV-based and HBV-based HCC. An increased 
expression of phase I modification enzymes (CYP2E, 
AKP1C4, EPHX1, and FMO3) were observed exclusively in 
HCV-positive HCCs, whereas expression of phase II-
conjugated reaction enzymes (UGT1A1, UGT2G10, and 
GPX2) were preferentially repressed in HBV-positive HCCs. 
Phase I and phase II reactions are metabolic pathways re-
sponsible for drug metabolism in the liver but also the me-
tabolization of xenobiotic carcinogens [24]. Phase I enzymes 
convert several pro-carcinogens to activated metabolites. 
Thus, the overexpression of Phase I modification genes   
suggests that this enhanced expression leads to a greater con-
tribution of carcinogenic metabolites to the mechanisms of 
HCV-specific hepatocarcinogenesis. In contrast, decreased 
expression of enzymes catalyzing phase II-conjugated reac-
tions suggests that the decreased expression of detoxification 
enzymes may be involved in the mechanisms of HBV-
specific tumorigenesis. This hypothesis was furthermore 
supported by Iizuka et al. [10] who also reported an in-
creased expression of phase I enzymes (CYP2E) in HCV-
induced HCCs compared to HBV-induced HCCs and a sig-
nificant reduction of detoxification-related genes in HBV-
associated HCC. Moreover, the same study reported, that a 
number of immune response–related genes (IFI27, OAS1, 
ISG15, and IFI14) were up-regulated in HCV-associated 
HCCs compared to HBV-associated HCCs and to non-
tumorous liver. Genes that may promote metastasis (MMP-9, 
VEGF, HMMR, TACSTD1, and MCAM) were up-regulated 
in HBV-associated HCC. Finally, this study was the first to 
report that imprinted genes such as H19 and IGF-2 were in-
creased in HBV-associated HCC in comparison to both 
HCV-associated HCC and non-tumorous liver. Delpuech   
et al. [8] tried to summarize the comparison of HBV- versus 
HCV- associated HCC by describing the involvement of 
different cellular pathways. In HCV-specific cancer a more 
heterogenous gene expression pattern was identified with an 
overexpression of the TGF- induced genes.  
  In conclusion, these results suggested that HBV and 
HCV lead to the development of liver cancer by different 
mechanisms. Key molecular mechanisms suggested by cur-
rently available publications include a blockade of the de-
toxification system [10], alteration of immune response 
mechanisms, inflammation, and specific genetic pathways 
such as TGF- pathway. The deregulation of imprinted 
genes furthermore suggested imprinting has a role to play in 
the development of HCC as well.  
GENE EXPRESSION PROFILES ASSOCIATED WITH 
DIFFERENT HISTOLOGICAL GRADES OF HCC 
AND PRECANCEROUS DYSPLASTIC NODULES 
  It has repeatedly been proposed that tumorigenesis is a 
multistep process that often involves a complex series of 
multiple and diverse genetic alterations. Best analyzed are 
the multi-step changes during the development of colorectal 
carcinoma where at least seven sequential genetic alterations 
are proposed [25].  
  Concerning HCC progression multiple studies have ana-
lyzed global transcription levels in the context of different 
histological grades and precancerous nodules (Table 1). 
Wurmbach et al. [11] reported that the onset of HCC (dys-
plasia vs early HCC) was associated with major changes in 
gene expression as summarized in Table 1. Pathway analysis 
showed that early HCC may be distinguished from dysplasia 
by a significant down-regulation of components of the Toll-
like receptor pathway, Jak/STAT pathway, TGF pathway, 
and the insulin-signaling pathway. In contrast, components 
of the Wnt-signaling pathway were up-regulated. Progres-
sion of cancer was characterized by strong up-regulation of 
proliferation related genes. Many studies used Edmonson-
Steiner histopathological classification system [26] to dis-
criminate well- to poorly differentiated HCCs (Edmonson 
grade GI to IV). Yu et al. [27], reported that the transition 
from liver cirrhosis to GI or GII HCC is associated with up-
regulation of molecular chaperone genes including CCT5, 
HSPCG, CCT3, HSPCA, DNAJBII, HSPBI, and TOMM. 
Generally molecular chaperones, primarily members of the 
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of survival and apoptotic pathways [28]. Hsp70 has been 
reported to be a sensitive marker for the differential diagno-
sis of early HCC from a precancerous lesion or a non-
cancerous liver [29]. This work further suggested that a dete-
rioration of immune surveillance and apoptosis occurs at an 
early stage of HCC development, as many apoptosis and 
major histocompatibility complex related genes were down-
regulated during the transition from liver cirrhosis to GI or 
GII HCC [27]. Nam et al. [30] reported a series of 120 genes 
to be classifiers for distinguishing between low- (LGDN) 
and high grade dysplastic nodules (HGDN) and also between 
HGDN and GI HCC. Accuracy of these classifiers were 
95%. Moreover, a 120-gene molecular signature in HCC 
specimens could discriminate effectively (with 91% classifi-
cation accuracy) between GI-GII and GII-GIII HCC as well. 
Finally, Okabe et al. [9] compared GI to GII or GIII HCC 
and identified decreased levels of apoptosis related proteins 
(Table 1) in moderately-to-poorly differentiated HCC, sup-
porting the hypothesis that a reduced rate of apoptosis may 
be a major characteristic of tumor progression. 
DISCOVERING NOVEL SUBTYPES OF HCC 
  Several studies have demonstrated that HCC may be 
subdivided into at least two prognostically diverse subgroups 
based on gene expression patterns. Characterizing these mo-
lecular subgroups by microarray studies is essential since 
these subgroups may not be distinguishable by conventional 
histology but still potentially respond differently to treat-
ment. Thus, a clearer and better characterization of these 
diverse HCC subgroups may be crucial to entering an era of 
personalized HCC treatment, with the promises of higher 
efficacy, with the added benefit of fewer side effects. Lee  
et al. [31] identified a novel subtype of HCC that shared 
gene expression patterns with fetal hepatoblasts. Further-
more, expression of well-known markers of hepatic oval 
cells, and the early progenitors of adult liver stem cells en-
abled the authors to suggest that this subtype of HCC may 
arise from hepatic progenitor cells. Interestingly, based on 
the hepatoblast specific gene expression signature, HCC in-
dividuals could be subdivided into 2 subpopulations with 
significant differences in overall survival. HCC individuals 
who expressed the hepatoblast signature had a poorer prog-
nosis. The complete signature however comprised 907 
genes. A recent study by Yamashita et al. [32] classified 
HCCs in 4 groups based on EpCAM expression and patients’ 
serum levels of -fetoprotein (AFP). The same group had 
previously described EpCAM to be an early biomarker of 
HCC. 35% of HCC cases express EpCAM [33]. Gene ex-
pression analysis in these subgroups showed that each of 
these 4 subgroups had a unique expression pattern with fea-
tures resembling various stages of hepatic lineages such as 
hepatic stem cell-like HCCs, bile-duct epithelium-like 
HCCs, hepatocyte–like HCCs, and mature hepatocyte-like 
HCCs. These 4 subgroups were each associated with a dis-
tinct prognosis. Hepatic stem cell-like HCCs and hepatocyte-
like HCCs had poor prognosis, while hepatocyte-like HCCs 
and bile-duct epithelium- like HCCs had fair and good prog-
nosis, respectively [32]. Together these recent developments 
in microarray analysis of larger HCC datasets provide new 
insights into the potential cellular origin of HCCs. They 
demonstrate the presence of prognostically relevant sub-
groups, which were distinguishable only by means of genetic 
Table 1.  Genes Expression Profile Studies Associated with Different Histological Grades of HCC and Precancerous Dysplastic 
Nodules 
Study Upregulated  Downregulated 
Wurmbach et al. [11], 
Transition from dysplasia to early 
cancer 
Genes involved in cell cycle, protein biosynthesis and 
RNA processing, cell division, DNA replication, protein 
modification, ubiquitin cycle, chromatin remodeling, wnt 
pathway 
Genes involved in cytokine-cytokine receptor interaction, 
Ca signaling, Jack/STAT pathway, Toll-like receptor 
pathway, TGF- pathway, insulin growth pathway 
Wurmbach et al. [11], 
Transition from early to advanced 
cancer 
Genes involved in cell proliferation, DNA repair and 
replication (PRIM1, PRIM2), ubiquitin cycle, RNA proc-
essing and cell cycle regulation (ASPM, PTTG1, CCNB1, 
CDKN2C, CDKN2A) 
 
Yu et al. [27], 
Transition from cirrhosis to well-
to-moderately differentiated HCC 
Molecular chaperone genes (CCT5, HSPCG, CCT3, 
HSPCA, DNAJB11, HSPB, TOMM) and tumor-related 
genes (EFNA1, MDK, RBM17, FDPS, p8, LASS2 anti-
metastasis gene) 
Tumor suppressor and apoptosis-related genes (STAT1, 
IGFBP7, THY28 and DDB1), genes related to the major 
histocompatibility complex (HLA-DRB3, HLA-DPA1, 
HLA-DRA), liver specific genes 
Yu et al. [27], 
Transition from well-to-moderately 
differentiated to poorly differenti-
ated HCC 
Tumor progression-related genes (LAPT5, CD74, UBEIL, 
PRG1, DKK1, LAMB1) and metastasis or invasion genes 
(including S100A11, S100A6, RGS19/P1, TIMP2) 
 
Okabe et al. [9], 
Transition from well differentiated 
to moderately-to-poorly differenti-
ated HCC 
Apoptosis related proteins (TNFSF10, TNFSF14, 
GADD34, CFLAR, CLU, CASPC, phosphatidylserine 
receptor) 
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signatures, not by histology alone. However, these studies 
describe completely different and at the same time large sig-
natures. Thus, the challenge remains to isolate key identifiers 
of the diverse subgroups that are present in multiple datasets, 
and also to reduce the number of genes relevant to a gene 
signature, as this will promote bringing these signatures into 
clinical practice. 
GENE EXPRESSION PROFILE STUDIES ASSOCI-
ATED WITH METASTASIS 
  Metastasis of HCC fundamentally changes the prognosis 
of the tumor as surgery is no longer an option, and treatment 
of metastasized HCC is limited to palliation. Thus, identify-
ing genetic signatures associated with metastasis and subse-
quently being able to target the corresponding genetic proc-
esses would mean a significant improvement in HCC ther-
apy.  
  Diverse DNA microarray studies have reported many 
genes implicated in tumor metastasis [34-39]. RhoC-
GTPase, Granulin-epithelin precursor (GEP), Vimentin 
(VIM), and Platelet-derived growth factor receptor alpha 
(PDGFRA) were identified as being over-expressed in 
highly metastatic HCC and therefore may be considered for 
future strategies targeting the metastatic potential of HCC 
[34-39]. Besides, strong GEP expression was associated with 
large HCCs, venous infiltration, and early intrahepatic recur-
rence. A recent microarray study reported 4 genes (HLA-
DRA, HLA-DRB1, HLA-DG, and HLA-DQA) of the same 
family of HLA class II antigens to be down-regulated in 
HCCs with early intrahepatic recurrence [40]. In particular, 
low levels of HLA-DR protein in tumor cells correlated posi-
tively with transcription levels of the HLA-DRA gene. This 
tended to be associated with early intrahepatic metastasis and 
advanced tumor stage [40]. 
GENE EXPRESSION PROFILE STUDIES ASSOCI-
ATED WITH INTRAVENOUS INVASION 
  Venous invasion (VI), particularly portal venous invasion 
(PVI) is a hallmark of the intrahepatic spread of HCC cells, 
and therefore of poor outcome [41]. A better understanding 
of the underlying genetic mechanisms may in the future at 
least help to limit the growth and metastasis of HCC, and 
help keep patients in disease stages eligible for surgery or 
transplantation for longer periods of time. 
  Genome-wide gene expression profile studies identified a 
number of genes associated with venous invasion (Table 2). 
Ho et al. [42] compared gene expression profiles between 
HCC specimens with VI and HCC specimens without VI, 
and identified 14 genes essentially related to venous inva-
sion. Among these genes, 3 were related to cell growth 
(SLC4A7, RAB38, and RYR), while individual genes were 
involved in biosynthesis processes in human liver and mus-
cle (AMPD3), and in oxidative-DNA damage (8-OHdG). 
Interestingly, the genetic signatures of these 14 genes in 
HCC specimens could effectively discriminate patients at 
high risk of VI development or recurrence after curative he-
patectomy [42]. Chen et al. [13] reported 91 genes that signi-
ficantly correlated with the presence of VI. Most of these 
genes had functions associated with cell proliferation, while 
one gene was involved in the breakdown of extracellular 
matrix (MMP-14), and another one had antiangiogenic and 
antiproliferative activity (ADAMTS1). Okabe et al. [9] iden-
tified 151 genes associated with VI. This group of genes, 
with mostly unknown functions (110 genes), contained 3 
members of small GTPase-related genes (RhoC, RhoGAP8 
and ARHGEFG). RhoC-GTPase was found to be up-
regulated in HCC specimens with VI compared to HCC 
specimens without VI, while ARHGAP8 and ARHGEFG 
were preferentially down-regulated in VI tissues in compari-
son to non-VI tissues. Over-expression of RhoC in HCC 
specimens was recently reported to be strongly correlated 
with HCC venous invasion and metastasis [36]. Although the 
function of ARHGAP8 and ARHGEFG is unknown, ARH-
GAP8 is thought to inhibit the Rho-signaling pathway; hence 
reduced expression of ARHGAP8 may also results in Rho-
mediated tumor invasion. These findings led the authors to 
assume that controlling the Rho-pathway may suppress tu-
mor invasion and subsequent metastasis [9]. Tsunedomi   
et al. [43] identified 35 differentially-regulated genes related 
to portal venous invasion (PVI). These genes were involved 
in apoptosis and stress response (SGK, API5, GADD45B), 
cell proliferation (RAN, NUDC), oncogenesis (DDXI), and 
signal transduction (RHO6). Interestingly, a gene called in-
hibitor of DNA binding 2 (ID2), was found to be signifi-
Table 2.  Genes Related to Venous Invasion of HCC 
Study Upregulated  Downregulated 
Ho et al. [42] 
Tumor specific antigen (MAGE 9), oxidative DNA damage (8-
OHdG), proliferation regulator (TAFB4), growth factors (G-CSFR-
1), cell growth (SLC4A7, RAB38, RYR), and potent mitogen in-
hibitor (Thrombin inhibitor) 
KIAA1441 
Chen et al. [13] 
Genes associated with proliferation and in breakdown of extracellu-
lar matrix (MMP-14) 
Genes encoding liver-specific proteins (CYPs) and antian-
giogenic activity (ADAMTS1) 
Okabe et al. [9]  Gene encoding small GTPase enzyme (RhoC-GTPase) 
Genes encoding small GTPase enzyme (ARHGAP8, ARH-
GEFG) 
Tsunedomi et al. [43] 
Genes involved in apoptosis and stress response (API5), cell prolif-
eration (RAN, NUDC), and oncogenesis (DDX1) 
Genes involved in apoptosis and stress response (SGK, 
GADD45B) and signal transduction (RHO6) Microarray in HCC  Current Genomics, 2010, Vol. 11, No. 4    265 
cantly down-regulated in HCC specimens with PVI. This is 
in accordance with a recent report [44] demonstrating that 
ID2 protein levels decrease in parallel with HCC progres-
sion. ID proteins are negative regulators of cell growth and 
cell differentiation [45-48]. 
PREDICTION STUDIES TO DEVELOP PREDICTORS 
FOR HCC OUTCOME 
  Gene signatures in HCC tissues or noncancerous hepatic 
surrounding tissues, highly associated with prediction of 
clinical outcome (such as recurrence or overall survival after 
surgical resection of tumor) have been designated “predic-
tors”. Prediction studies aim to build a predictor and to 
evaluate its performance on an independent set of HCC pa-
tients [49]. Therefore, these studies use a training-validation 
approach in which a predictor is built on the basis of infor-
mation from training samples and its predictive power is 
evaluated on an independent sample set [49]. Several kinds 
of prediction studies have been performed and are summa-
rized below. 
STUDIES PREDICTING RECURRENCE AFTER 
SURGICAL RESECTION OF THE TUMOR  
  The poor outcome of HCC patients results partly from 
post-surgical recurrence of the primary tumor. Prediction 
studies identified multiple gene signatures in cancerous or 
noncancerous hepatic tissues which may serve as predictive 
tools to determine post-surgical recurrence. These signatures 
may aid in identifying patients most likely to benefit from 
surgery. Several studies used venous invasion as a cancer 
characteristic to build a predictor for recurrence after surgi-
cal resection of the tumor. Vascular invasion (VI) in pathol-
ogy specimens is a well-known unfavorable prognostic fac-
tor for HCC recurrence [42]. Based on the hypothesis that a 
gene expression profile for VI in HCC specimens can predict 
post-surgical recurrence, Ho et al. [42], identified a gene 
signature in cancerous hepatic tissues which consists of 14 
genes essentially related to vascular invasion (VI). This sig-
nature can provide an accurate discrimination between pa-
tients with high and low risk of VI development and recur-
rence after curative hepatectomy. Budhu et al. [50], reported 
a 17-gene signature expressed in noncancerous hepatic tis-
sues with venous metastasis, capable of significantly dis-
criminating patients who are likely to experience recurrence 
within 3 years after surgical hepatectomy (79% sensitivity). 
This predictive signature, largely contributed to by inflam-
matory and immune response-related genes, can also predict 
venous metastases developed several years after resection of 
the tumor. A recent study [51] revealed overexpression of 
Aurora kinase B, a chromosome passenger protein kinase, in 
HCC tissues, to be the most significant predictor of the ag-
gressive recurrence of HCC after surgical hepatectomy. 
Japanese authors used early intrahepatic recurrence (IHR) as 
a clinical outcome to build a predictor [49]. Iizuka et al. [52] 
reported a gene signature of 12 genes related to immune re-
sponse, expressed in cancerous tissues, which can effectively 
detect HCC patients at high risk of early IHR within 1 year 
after curative surgery. Accuracy in validation test was 92%. 
Kurokawa  et al. [53] identified a 20-gene signature ex-
pressed in HCC tissues, capable of predicting early IHR 
within 2 years after HCC resection. This gene signature, 
mainly consisting of E-cadherin and immune response-
related genes, predicted early IHR with 73% accuracy. So-
mura  et al. [54] reported a 3-gene signature expressed in 
HCC areas to be predictor of early IHR within 1 year after 
surgery. This 3-gene- combination (HLA-DRA, DDX17, and 
LAPTM5) predicted early IHR with 81% accuracy in the 
validation group. Finally, Claudin-10 (CLDN10), a gene 
encoding integral membrane protein and tight junction 
strands, was found to be over-expressed in recurrent HCC 
tumors after curative hepatectomy [37]. Therefore, the 
authors proposed that CLDN10 could serve as a molecular 
marker for metastatic potential, and recurrence, after curative 
resection of the tumor. 
STUDIES PREDICTING OVERALL SURVIVAL AF-
TER SURGICAL HEPATECTOMY 
  Few expression studies have focused on the potential role 
of gene signatures as predictors of overall survival after sur-
gical resection of the tumor. Lee et al. [55] reported that a 
406-gene expression signature can effectively divide HCC 
patients into 2 subpopulations, with significant differences in 
survival. Genes associated with cell proliferation, apoptosis, 
histone modification, and ubiquitination provided the most 
accurate discrimination between subpopulations. A novel 
survival-related subpopulation of HCC patients which was 
associated with a poor prognosis, and was characterized by a 
gene expression profile resembling that of fetal hepatoblast, 
was added to the former classification [31].  
  In another study, a signature of 111-Met regulated genes 
enabled prediction of survival in HCC patients [56]. The 
presence of the Met-gene signature defined a subpopulation 
of HCC patients who had a worse survival rate compared to 
patients in whom Met-signature was absent. 
STUDIES PREDICTING CHEMOTHERAPEUTIC 
RESPONSE IN PATIENTS WITH ADVANCED HCC 
  Chemotherapeutic treatment is often associated with se-
vere side effects and in light of limited prognosis, treatment 
with the most effective drug may be crucial. Thus, microar-
ray based prediction of effectiveness of drugs in individual 
patients may be the key to a more specific treatment. In the 
pre-sorafenib era, combination chemotherapy with 5-
fluorouracil (5-FU) and interferon- (IFN-) has been dem-
onstrated to be beneficial in some patients [51, 55]. Kuroka-
wa et al. [53] revealed that a 63-gene-signature could effec-
tively (85% accuracy in validation group) select patients 
eligible for this treatment. These 63 predictive genes inclu-
ded some genes that had previously [57-64] been reported to 
be associated with sensitivity to 5-FU (MMP-9, HK2, 
TNFSF6) or IFN- (CALM-1, ENPEP, BIRC4, OASL). Mo-
riyama et al. [65] reported that gene expression of 27 predic-
tive genes could select patients for combination 5-FU/ IFN- 
therapy. Among these genes, 10 were associated with sensi-
tivity to 5-FU alone. However, with sorafenib being the first 
drug showing a significant improvement in survival and 
other targeted therapy concepts being investigated in clinical 
trial, the data relating to 5FU is likely to become less rele-
vant. Rather, the hepatologic community needs data on 
treatment response to sorafenib, depending on the genetic 
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the Asian trial [66] demonstrated a significantly lower bene-
fit for treatment with sorafenib than previously described 
[66]. Data demonstrating this has yet to be generated.  
POTENTIAL BIOMARKERS FOR EARLY HCC DI-
AGNOSIS 
  HCC is a challenging malignancy which possesses a 
dismal outcome, partly due to the poor identification of 
early–stage HCC. The combination of serum AFP and ultra-
sonography is widely used as a screening procedure for the 
presence of HCC in high risk populations [67, 68]; however 
it is not reliable for the early detection of HCC [69, 70]. 
Clearly, there is an urgent need for novel serologic HCC 
biomarkers that have a sufficient sensitivity and specificity 
to aid in the early diagnosis of HCC. DNA microarray stud-
ies attempted to identify novel serological markers, by tar-
geting genes that are characteristically highly expressed in 
HCC tissues and whose products are secreted in serum. Jia  
et al. [69] identified 5 genes (GPC3, PEG10, MDK, SER-
PINI1, and QP-C), encoding known serum proteins, over-
expressed in most HCC cases, including those with normal 
AFP. A combined score using these 5 genes can accurately 
differentiate non-cancerous hepatic tissues (with 100% accu-
racy) and HCCs (with 71% accuracy). Lee et al. [71] re-
ported that cystatin B (CSTB) could serve as a potential se-
rum marker in HCC. CSTB is specifically over expressed in 
most HCCs and is also elevated in the serum of a large pro-
portion of HCC patients. The specificity and sensitivity of 
CSTB were 85,5% and 53,1% respectively, in distinguishing 
between patients with HCC and those with non-malignant 
chronic liver disease. It will be of significant interest having 
future studies which aim to combine these diverse markers, 
in order to maximize their diagnostic accuracy.  
CONCLUSION AND PERSPECTIVES 
  Microarray studies have successfully shed light on vari-
ous aspects of the molecular mechanisms of hepatocellular 
carcinoma such as tumor development, the identification of 
novel molecular subgroups, and also genetic profiles associ-
ated with metastasis and venous invasion. One of the major 
problems in large microarray analysis experiments remains 
the comparability between different data sets. The challenge 
remains to extract a few essential genes from these large lists 
of regulated genes that will aid in early detection, subclassi-
fication and determining prognosis of HCC. Successful tar-
geting may ultimately lead to further advances in preventive 
medicine and targeted personalized therapy of HCC. Further 
support in this direction may come from advances in other 
high-throughput technologies in genomics, especially next 
generation sequencing, proteomics, and also in the develop-
ment of novel bioinformatics algorithms. Even more, inte-
grating the diverse data from microarray data, genome wide 
mutation screens, and the increasingly available proteome 
data will provide further support. Combining this with clini-
cal data will present novel perspectives on the diagnosis and 
treatment of HCC in the next decade.  
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